Impact of FDG PET on Defining the Extent of Disease and on the Treatment of Patients with Recurrent or Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Impact of FDG PET on Defining the Extent of Disease and on the Treatment of Patients with Recurrent or Metastatic Breast Cancer

Published:2004-08 Issue:2 Volume:183 Page:479-486
ISSN:0361-803X
Container-title:American Journal of Roentgenology
language:en
Short-container-title:American Journal of Roentgenology

Author:

Eubank William B.,Mankoff David,Bhattacharya Mallar,Gralow Julie,Linden Hannah,Ellis Georgiana,Lindsley Skyler,Austin-Seymour Mary,Livingston Robert

Publisher

American Roentgen Ray Society

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference31 articles.

1. Moon DH, Maddahi J, Silverman DHS, et al. Accuracy of whole-body [fluorine-18]-FDG PET for the detection of recurrent or metastatic breast carcinoma.J Nucl Med1998; 39:431-435

2. Eubank WB, Mankoff DA, Takasugi J, et al. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.J Clin Oncol2001; 19:3516-3523

3. Bender H, Kirst J, Palmedo H, et al. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.Anticancer Res1997; 17:1687-1692

4. Comparison of fluorodeoxyglucose positron emission tomography and ‘conventional diagnostic procedures’ for the detection of distant metastases in breast cancer patients

5. The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and characterization of 64Cu-labeled Geldanamycin derivative for imaging HSP90 expression in breast cancer;Nuclear Medicine and Biology;2024-09

2. Role of [18F]FDG PET/CT in patients with no special type breast cancer: Literature review and comparison between guidelines;The Breast;2024-09

3. Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)✰;Journal of the National Cancer Center;2023-12

4. First-line treatment of hormone-sensitive metastatic breast cancer;Revisiones en Cáncer;2023

5. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer;Seminars in Nuclear Medicine;2022-09